The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00005120
Verified June 2001 by NIH AIDS Clinical Trials Information Service. Recruitment status was: Active, not recruiting
The purpose of this study is to see if it is safe and effective to give calanolide A to HIV-infected adults who have not used anti-HIV drugs in the past.
Condition or disease
Drug: Calanolide A
Patients are randomized to receive (+)-calanolide A or placebo for 21 days. All patients may elect to receive an open-label, 3-month course of approved retroviral therapy (up to triple-drug therapy) to be selected by, and administered under the care of, the patients' physicians. If the patient has no insurance coverage or does not wish to utilize his/her insurance for anti-HIV medications, Sarawak MediChem Pharmaceuticals will provide these medications at no charge for up to 3 months.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients may be eligible for this study if they:
Are at least 18 years old.
Agree to use effective methods of birth control during the study.
Have a CD4 cell count of 200 cells/mm3 or more.
Have HIV levels of 5000 copies/ml or more.
Patients will not be eligible for this study if they:
Have abnormal blood tests.
Have had a reaction to study medication.
Have a history of opportunistic (AIDS-related) infection or cancer.
Are being treated for active pulmonary tuberculosis.
Have a fever of 39 degrees C or more within 14 days of beginning study treatment.
Are unable to take medications by mouth.
Have an abnormal chest X-ray or ECG within 30 days of beginning study treatment.
Have hepatitis, hemophilia, or other blood disorder.
Have significant heart, stomach, intestinal, liver, nerve, or kidney problems.
Have a condition which may affect ability to participate in this study, such as drug or alcohol abuse or a serious mental disorder.
Have taken anti-HIV drugs in the past.
Are taking certain medications.
Have had a blood transfusion within the 3 months prior to entering the study.
Have had radiation or chemotherapy within 16 days before the screening visit or plan to receive such treatment during the study.